Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
First patients enrolled in a multinational Phase 3 clinical trial of dasiglucagon
Dasiglucagon is a potential first-in-class glucagon analog suitable for a ready-to-use rescue pen to treat severe hypoglycemia
Copenhagen, July 3, 2017 - Zealand Pharma A/S ("Zealand") announces the initiation of a multinational Phase 3 clinical trial of dasiglucagon in four countries (Austri